| __timestamp | Ascendis Pharma A/S | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 165772000 |
| Thursday, January 1, 2015 | 9415000 | 196614000 |
| Friday, January 1, 2016 | 11504000 | 303251000 |
| Sunday, January 1, 2017 | 13482000 | 366406000 |
| Monday, January 1, 2018 | 25057000 | 434407000 |
| Tuesday, January 1, 2019 | 48473000 | 468711000 |
| Wednesday, January 1, 2020 | 76669000 | 516922000 |
| Friday, January 1, 2021 | 160180000 | 739560000 |
| Saturday, January 1, 2022 | 221227000 | 1002140000 |
| Sunday, January 1, 2023 | 264410000 | 1161300000 |
| Monday, January 1, 2024 | 284545000 | 1242157000 |
Unlocking the unknown
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Over the past decade, Incyte Corporation and Ascendis Pharma A/S have demonstrated contrasting trajectories in their SG&A expenditures. From 2014 to 2023, Incyte Corporation's SG&A expenses surged by approximately 600%, peaking at over $1.16 billion in 2023. This reflects their aggressive expansion and investment in administrative capabilities. Meanwhile, Ascendis Pharma A/S, though smaller in scale, exhibited a remarkable 4,100% increase in SG&A expenses, reaching $264 million in 2023. This rapid growth underscores their strategic push into new markets and product development. As these companies continue to evolve, their cost management strategies will be pivotal in shaping their competitive edge and financial health.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation